VISTOGARD
LOE Approachinguridine triacetate
NDAORALGRANULEPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISTOGARD (uridine triacetate) is an oral granule formulation approved in December 2015 for emergency treatment of fluorouracil and capecitabine overdose or toxicity. It works by providing exogenous uridine to bypass the toxic metabolic pathway and reduce systemic exposure to active metabolites. The drug addresses a rare but critical medical emergency in oncology.
LOE Approaching10mo to LOE
Product is approaching loss of exclusivity in August 2027 with minimal linked job openings, indicating a small, stable team with limited growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.